Mobile

Multicenter, single-arm, two-stage phase II trial of RAD001 (everolismus) with Glivec® in Glivec®-resistant patients with progressive GIST

Update Il y a 4 ans
Reference: EUCTR2005-004837-16

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the response to treatment with RAD001 plus Glivec® at 4 months. Response is defined as progression-free survival (PFS) at 4 months.

Inclusion criteria

  • gastrointestinal stromal tumors (GIST)

Links